Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster lunch

1520 - High-throughput proteome identifies ANHAK as a novel biomarker for bladder urothelial carcinoma diagnosis in liquid-based cytology. (27P)


18 Nov 2017


Poster lunch


Translational Research;  Urothelial Cancers


Hyebin Lee


Annals of Oncology (2017) 28 (suppl_10): x7-x15. 10.1093/annonc/mdx653


H. Lee1, H. Ryu2, D. Han3

Author affiliations

  • 1 Radiation Oncology, Kangbuk Samsung Hospital Sungkyunkwan University, 110-746 - Seoul/KR
  • 2 Pathology, Seoul National University Hospital (SNUH)-Yongon Campus, 110-744 - Seoul/KR
  • 3 Proteomics Core Facility, Biomedical Research Institute, Seoul National University Hospital, Seoul/KR


Abstract 1520


Urine cytologic examination is the most widely used noninvasive pathologic test to screen bladder urothelial carcinoma (BLCA). However, inadequate diagnostic accuracy remains the major challenge to be solved. We performed high-throughput proteomcis in ten paired samples of BLCA and benign urothelial lesion (BUL) to identify ancillary proteomic markers in liquid-based cytology (LBC).


All samples were analyzed by in-depth quantitative protomics mass spectrometry (MS) to indicate differentially expressed proteins (DEP) between two groups. MS data were analyzed using a combination of MaxQuant and Perseus computational platforms, and a total of 4,839 proteins were identified, and 112 DEP were confirmed to be significantly altered proteins in BLCA group compared with BUL group (FDR q value


As a consequence, 12 proteins including ACACA, AHNAK, ATP1A1, DSG1, EIF4A1, EPPK1, HSP90AB1, MYH14, RPS8, TOP2B, TUBB and YWHAZ were identified as putative candidates to apply to immunostaining. To determine immunocytochemical expression in LBC, protein expression was screened according to The Human Protein Atlas and six proteins finally enrolled to validate immunoreactivity in independent LBC cohorts where AHNAK was confirmed a unique intracellular protein translocation in immunostaining depending on tumor or non-tumor cells.


This finding provided a new biomarker which can be applicable to discriminate between BLCA and BUL in LBC. To our knowledge, the present study provides the first evidence of the identification of a clinical biomarker from LBC based on in-depth proteomics.

Clinical trial identification

Legal entity responsible for the study





All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.